Clinical Focus

  • Pediatric Cardiology
  • Pediatric Heart Failure, Transplant and MCS

Academic Appointments

Boards, Advisory Committees, Professional Organizations

  • Member, Alpha Omega Alpha Honor Medical Society (2011 - Present)
  • Member, International Society of Heart and Lung Transplant (2016 - Present)
  • Member, American Heart Association (2018 - Present)
  • Member, American Society of Transplantation (2018 - Present)

Professional Education

  • Board Certification: American Board of Pediatrics, Pediatric Cardiology (2018)
  • Board Certification: American Board of Pediatrics, Pediatrics (2014)
  • Senior Fellowship, Boston Children's Hospital, Heart Failure & Heart Transplant (2018)
  • Fellowship, Boston Children's Hospital, Pediatric Cardiology (2017)
  • Residency, Boston Combined Residency Program (Boston Children's Hospital), Pediatrics (2014)
  • MD, University of Washington School of Medicine (2011)


All Publications

  • Incidence, predictors, and outcomes after severe primary graft dysfunction in pediatric heart transplant recipients JOURNAL OF HEART AND LUNG TRANSPLANTATION Profita, E. L., Gauvreau, K., Rycus, P., Thiagarajan, R., Singh, T. P. 2019; 38 (6): 601–8
  • Extracorporeal membrane oxygenation use in the first 24hours following pediatric heart transplantation: Incidence, risk factors, and outcomes. Pediatric transplantation Godown, J., Bearl, D. W., Thurm, C., Hall, M., Feingold, B., Soslow, J. H., Mettler, B. A., Smith, A. H., Profita, E. L., Singh, T. P., Dodd, D. A. 2019: e13414


    Primary graft dysfunction following HTx is associated with significant morbidity and mortality. This study aimed to assess the incidence of, risk factors for, and outcomes of children requiring ECMO within 24hours of HTx. This study utilized a linked PHIS/SRTR database of pediatric HTx recipients (2002-2016). Post-HTx ECMO was identified using inpatient billing data. Logistic regression assessed risk factors for post-HTx ECMO. Kaplan-Meier analyses assessed in-hospital mortality and post-discharge survival. A total of 2820 patients were included with 224 (7.9%) requiring ECMO. Independent risk factors for post-HTx ECMO include age <1year (aOR: 2.2, 95% CI: 1.3-3.7, P=0.006) or 1-5years (aOR: 2.1, 95% CI: 1.3-3.4, P=0.002), and ECMO support at HTx (aOR: 27.4, 95% CI: 15.2-49.6, P<0.001). Survival to discharge decreased with increasing duration of post-HTx ECMO support; 89% for 1-3days, 79.1% for 4-6days, 63.2% for 7-9days, and 18.8% for ≥10days. There was no difference in long-term survival for patients requiring post-HTx ECMO who survived to hospital discharge (P=0.434). There are identifiable risk factors associated with the need for ECMO in the post-HTx period. Length of time on ECMO post-HTx is strongly associated with the risk of in-hospital mortality. Patients who require ECMO early post-HTx and survive to discharge have comparable outcomes to patients who did not require ECMO.

    View details for PubMedID 30973190

Latest information on COVID-19